Skip to main content
Clinical Trials/NCT03036241
NCT03036241
Completed
Not Applicable

Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study (Dialysis Fistulae)

Helsinki University Central Hospital0 sites39 target enrollmentJanuary 23, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Vascular Access Complication
Sponsor
Helsinki University Central Hospital
Enrollment
39
Primary Endpoint
TLR
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The purpose of this study is to determine whether the use of drug-eluting balloons is effective in the treatment of (re)stenosis in dialysis fistulae.

Detailed Description

Drug-eluting devices have proved beneficial in the treatment of stenosis in native coronary and lower limb arteries. Stenosis and restenosis is a known problem in dialysis fistulae and drug-eluting devices might be beneficial in this field as well. In the procedure a conventional balloon is passed through the stenosis which is then dilated. After this patients are randomized before a second dilatation with either a conventional balloon or a drug-coated balloon. The stenosis is evaluated preoperatively and followed up by means of ultrasound by a vascular technician. Follow-up will end at 12 months.

Registry
clinicaltrials.gov
Start Date
January 23, 2013
End Date
February 28, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maarit Venermo

Professor of Vascular Surgery

Helsinki University Central Hospital

Eligibility Criteria

Inclusion Criteria

  • Any dialysis access w/ native vessels warranting intervention

Exclusion Criteria

  • Previous PTA with drug-eluting balloon, thrombolysis, coagulopathy

Outcomes

Primary Outcomes

TLR

Time Frame: 12 months

Target lesion revascularization, ie. re-intervention to the same lesion

Occlusion of access

Time Frame: 12 months

Any loss of dialysis access due to thrombosis

Secondary Outcomes

  • Primary assisted patency(12 months)
  • Death(12 months)

Similar Trials